longevity
April 2026
The First Partial Epigenetic Reprogramming Therapy Has Entered Human Trials
Life Biosciences initiated Phase 1 trials of ER-100 in Q1 2026 — the first time partial epigenetic reprogramming using Yamanaka factors (OCT4, SOX2, KLF4) has been tested in humans. The trial targets optic neuropathies as its regulatory entry point, but the platform is designed to restore cells to a younger state across tissue types. In April 2026, the company closed $80M in financing to fund trial completion. This is categorically different from epigenetic clock measurement — it is the first clinical attempt to reverse biological age at the cellular level.
biohacking
April 2026
Meal Timing Shapes Biological Aging Across Multiple Organs — Nature Portfolio Study
A study published in npj Science of Food (Nature portfolio) analysed 14,012 adults from NHANES and found that eating the first and last meals later in the day is independently associated with faster biological aging — assessed across the body, heart, liver, and kidneys. Earlier last meals (before 9 p.m.) were protective, with peak effect between 3–5 p.m. for cardiovascular and somatic aging. Feeding windows longer than 8 hours correlated with elevated aging risk. Effects were strongest in adults over 40, making this directly actionable for anyone optimising their eating window for longevity.
supplements
April 2026
NMN + Apigenin: Stacking a CD38 Inhibitor With NAD⁺ Restores Muscle and Bone in Aged Mice
New research found that combining NMN (which raises NAD⁺) with apigenin (which blocks CD38, the enzyme that degrades it) restored muscle function, bone structure, and gut integrity in aged mice — with synergistic effects stronger than either compound alone. This reframes supplementation strategy from which NAD⁺ precursor to use, to how to protect NAD⁺ once raised. The finding is mechanistically distinct from NMN vs. NR comparisons and has direct implications for longevity protocol design, pending human trial confirmation.
Supplements
March 2026
NMN vs NR: What Five Years of Human Trials Have Settled
The NAD⁺ precursor debate has run for a decade. Longitudinal data from Washington University and Keio University now offers the clearest comparative picture yet — with meaningful implications for dosing, timing, and who actually benefits from supplementation.
Clinics
April 2026
Europe's Longevity Clinic Landscape: From the Alps to the Algarve
Lanserhof, Clinique La Prairie, SHA Wellness, LifeHub — European longevity medicine is no longer niche. A map of the continent's leading physician-led centres, their diagnostic methodologies, and what separates clinical rigour from luxury spa positioning.
Biohacking
March 2026
Biomarker-First: Why Supplement Stacks Without Data Are Guesswork
Testing before supplementing — the principle sounds obvious, yet most people spend thousands without baseline data. The case for a biomarker-driven approach to optimisation, and what the evidence says about personalised vs. generic protocols.
Longevity
February 2026
Biological Age vs. Chronological Age: The Epigenetic Clocks Gaining Clinical Traction
Horvath's clock, GrimAge, DunedinPACE — epigenetic age testing is moving from research tool to clinical diagnostic. What the markers actually measure, which show the strongest correlation with healthspan outcomes, and how to interpret your results.
Peptides
February 2026
GLP-1 Beyond Weight Loss: What the 2025 Cardiovascular Data Means for Longevity
Semaglutide and tirzepatide trials consistently show effects beyond metabolic control — reduced cardiovascular events, neuroprotective markers, anti-inflammatory profiles. What longevity clinicians are watching in the SELECT trial data and what it signals for 2026 protocols.
Regulatory
April 2026
EMA's June 2026 Peptide Guidelines: What European Consumers Need to Know
The European Medicines Agency's updated synthetic peptide classification takes effect June 1, 2026. What changes in practice, what it means for grey-market access, and the key compliance markers to verify in any supplier operating in the European market.